Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures

Abstract Neoadjuvant combination therapy with anti-PD-1 and anti-CTLA4 agents has significantly improved long-term survival in patients with metastatic melanoma, yet not all patients respond to treatment. Responders often exhibit upregulated baseline inflammatory signatures; however, these markers c...

Full description

Saved in:
Bibliographic Details
Main Authors: S. C. M. A. Wijnen, P. Dimitriadis, I. L. M. Reijers, A. M. Menzies, G. V. Long, L. F. A. Wessels, C. U. Blank
Format: Article
Language:English
Published: Springer 2025-06-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Online Access:https://doi.org/10.1007/s00262-025-04094-0
Tags: Add Tag
No Tags, Be the first to tag this record!